---
title: "AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer"
description: "AbbVie (ABBV) has announced an update on its Phase 1/2 clinical study of Etentamig, an investigational drug for multiple myeloma (MM). The study aims to evaluate the safety and efficacy of Etentamig, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254329650.md"
published_at: "2025-08-24T16:30:30.000Z"
---

# AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer

> AbbVie (ABBV) has announced an update on its Phase 1/2 clinical study of Etentamig, an investigational drug for multiple myeloma (MM). The study aims to evaluate the safety and efficacy of Etentamig, both as a monotherapy and in combination with other treatments, targeting relapsed or refractory MM. Approximately 440 participants will be involved globally, with the study starting on March 19, 2025. Positive results could enhance AbbVie's position in the MM treatment market and influence its stock performance.

Abbvie ((ABBV)) announced an update on their ongoing clinical study.

### Elevate Your Investing Strategy:

-   Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

AbbVie is conducting a Phase 1/2 open-label study to evaluate the safety and efficacy of Etentamig, an investigational drug for multiple myeloma (MM), a cancer affecting plasma cells in the blood. The study, titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma, aims to assess disease activity changes and adverse events in adult participants. This research is significant as it targets relapsed or refractory MM, a challenging condition with limited treatment options.

The study tests Etentamig administered intravenously, alone or in combination with other drugs like daratumumab, lenalidomide, dexamethasone, and carfilzomib. These combinations aim to enhance treatment efficacy and manage MM symptoms more effectively.

The study is designed as a randomized, parallel assignment with no masking, focusing primarily on treatment. It includes dose escalation and expansion phases across four substudies, involving approximately 440 participants globally.

Key dates for the study include its start on March 19, 2025, with the latest update submitted on August 18, 2025. These timelines are crucial for tracking the study’s progress and anticipating future developments.

This clinical update could positively influence AbbVie’s stock performance and investor sentiment, as successful results may strengthen its position in the MM treatment market. Competitors in the oncology space will likely monitor these developments closely.

The study is ongoing, with further details available on the ClinicalTrials portal.

## Trending Articles:

-   RDDT Lawsuit Alert! Class Action Lawsuit Against Reddit, Inc.
-   ‘Nvidia Is Best Positioned to Clear a High Bar,’ Says TD Cowen as it Raises PT Ahead of Q2 Print
-   IRBT Lawsuit Alert! Class Action Lawsuit Against iRobot Corporation

Disclaimer & DisclosureReport an Issue

### Related Stocks

- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 艾伯维｜8-K：2025 财年营收 612 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274816008.md) |
| 艾伯维在腹壁疝气试验中推进新的毒素疗法：投资者应关注哪些方面 | 艾伯维（AbbVie，股票代码：ABBV）正在进行一项针对 AGN-151607-DP 的二期临床试验，该疗法基于肉毒毒素，旨在改善腹股沟疝手术的结果。该研究评估了该药物在促进主要筋膜闭合而无需复杂修复技术方面的安全性和有效性。试验约有 2 | [Link](https://longbridge.com/en/news/275926867.md) |
| 每千次展示 60 美元！OpenAI 用高价拉开 “AI 广告” 大幕 | 为应对 AI 巨额开支，OpenAI 正式测试广告，CPM60 美元起步、最低投入 20 万美元，定位高端渠道，直接挑战谷歌万亿美元市场，WPP 等顶级代理已率先合作。但转型风险并存：需平衡用户信任，承诺不用私聊数据；对手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) |
| 伊本·阿尔·海赛姆医院全年收入为 301,281 第纳尔 | 伊本·海瑟姆医院公司 PSC (IBNH.AM)：伊本·海瑟姆医院财年税后净收入为 301,281 第纳尔；伊本·海瑟姆医院财年收入为 1210 万第纳尔 | [Link](https://longbridge.com/en/news/275996849.md) |
| 领先汽车配件的沉重债务负担加剧了流动性、再融资以及业务扭转的风险 | Advance Auto Parts Inc (AAP) 正面临重大财务风险，主要由于其沉重的债务负担，这可能限制流动性和融资渠道。这种情况可能迫使更多现金流用于偿债，而非投资，从而增加对经济衰退和潜在契约违约的脆弱性。在严峻的信贷环境中， | [Link](https://longbridge.com/en/news/275997122.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.